This study aimed to investigate the pivotal and well-established molecular breast cancer markers, ER, PR, and HER2, in the respective subtypes of human high-grade DCIS, aiming to identify those DCIS lesions that most probably will progress to IBC. This evidence concerns the gene ESR1 and inflammatory breast carcinoma.